The critical appraisal of cost-effectiveness by health care payers and their nominated agencies have applied pressure on health care developers to review health economics and outcomes research (HEOR) earlier in their clinical development plans to gain optimal pricing and reimbursement.
At Clinscience, our team have supported organisations navigate through the UK National Institute of Clinical Excellence (NICE) Health Technology Assessment (HTA). We have also supported pricing and reimbursement research commissioned by the French Ministry of Health and Social Affairs and also modelling for (HEOR) for agencies in the US and Asia.
